| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | RELIANT GLYCOSCIENCES LLC | 1716 WINGFIELD CIR | BIRMINGHAM | AL | 35242-5852 | SHELBY | USA | R44DK139874 | GalNAc-specific measurement of Galactose-deficient IgA1 as a Biomarker for IgA nephropathy | 000 | 1 | NIH | 12/5/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $977,756 ) |
| | 2024 | 2024 | RELIANT GLYCOSCIENCES LLC | 1716 WINGFIELD CIR | BIRMINGHAM | AL | 35242-5852 | SHELBY | USA | R44DK139874 | GalNAc-specific measurement of Galactose-deficient IgA1 as a Biomarker for IgA nephropathy | 000 | 1 | NIH | 6/18/2024 | $977,756 |
| | 2024 | 2023 | RELIANT GLYCOSCIENCES LLC | 1716 WINGFIELD CIR | BIRMINGHAM | AL | 35242-5852 | SHELBY | USA | R44DK126526 | Utilizing IgG Autoantibodies As Biomarkers In IgA Nephropathy | 000 | 3 | NIH | 8/29/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $616,309 ) |
| | 2023 | 2023 | RELIANT GLYCOSCIENCES LLC | 1716 WINGFIELD CIR | BIRMINGHAM | AL | 35242-5852 | SHELBY | USA | R44DK126526 | Utilizing IgG Autoantibodies As Biomarkers In IgA Nephropathy | 000 | 3 | NIH | 3/27/2023 | $616,309 |
|
| Issue Date FY: 2022 ( Subtotal = $667,669 ) |
| | 2022 | 2022 | RELIANT GLYCOSCIENCES LLC | 1716 WINGFIELD CIR | BIRMINGHAM | AL | 35242-5852 | SHELBY | USA | R44DK126526 | Utilizing IgG Autoantibodies As Biomarkers In IgA Nephropathy | 000 | 2 | NIH | 4/11/2022 | $667,669 |
| | 2022 | 2020 | RELIANT GLYCOSCIENCES LLC | 1716 WINGFIELD CIR | BIRMINGHAM | AL | 35242-5852 | SHELBY | USA | R43DK126526 | Utilizing IgG Autoantibodies as Biomarkers in IgA Nephropathy | 000 | 1 | NIH | 12/28/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $211,707 ) |
| | 2020 | 2020 | RELIANT GLYCOSCIENCES LLC | 1716 WINGFIELD CIR | BIRMINGHAM | AL | 35242-5852 | SHELBY | USA | R43DK126526 | Utilizing IgG Autoantibodies as Biomarkers in IgA Nephropathy | 000 | 1 | NIH | 6/19/2020 | $211,707 |
|
|
